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Chondroitin sulfate (CS) belongs to the group of glycosaminoglycans (GAGs), which are linear polysaccharides,
located in the extracellular matrix and on the cell surface. To study the structure and distribution of CS in human
skin and skin disorders, we have selected antibodies using phage display technique against CS. Four unique
human anti-CS single-chain antibodies were selected: IO3D9, IO3H10, IO3H12, and IO4C2. We determined their
amino acid sequence and evaluated their CS reactivity using ELISA and immunohistochemistry. Antibodies were
reactive with CS, but not with other GAGs except for IO4C2, which was also reactive with heparin. Antibody IO3D9
showed a strong reactivity with highly sulfated CS (CSE). All antibodies displayed a different staining pattern in rat
kidney, indicating the recognition of unique CS epitopes. In normal skin, the papillary dermis but not the reticular
dermis was strongly stained. Antibody IO3H12 also stained basal keratinocytes. We applied these antibodies to
study CS expression and localization in melanoma and psoriasis. A strong immunoreactivity with the extracellular
matrix of melanoma metastases could be observed for all four antibodies, while in atypical nevi a less extensive
reactivity with only the papillary dermis was observed. In psoriatic lesions, CS could be observed in the papillary
dermis and in the reticular dermis, whereas the speciﬁc location in the papillary dermis found in normal skin was
completely lost. In conclusion, human phage-display-derived anti-CS antibodies have been selected, characterized,
and applied to detect CS alterations in skin conditions. Altered CS composition was detected in melanoma and
psoriasis.
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Glycosaminoglycans (GAGs) are complex negatively
charged polysaccharides, which together with core proteins
form proteoglycans. GAGs can be grouped into five classes
by their basic disaccharide constitution. The different
classes are hyaluronate (HA), chondroitin sulfate (CS),
keratan sulfate (KS), heparan sulfate (HS)/heparin, and
dermatan sulfate (DS). GAGs are involved in processes
such as cell signaling, cell adhesion, and cell migration
(Tumova et al, 2000). This is mediated by the ability of GAGs
to specifically bind and modulate a large number of proteins
(Conrad, 1998). Proteins are bound as a result of chemical
modifications superimposed on the saccharide backbone.
GAGs regulate four aspects with respect to the proteins
they bind: localization, modification, stabilization, and
activation (Tumova et al, 2000). For instance, growth factors
can be stored and activated by GAGs in the extracellular
matrix and at the cell surface, thus controlling cell
proliferation, differentiation, and regulation of synthesis
and remodeling of the extracellular matrix (Taipale and
Keski-Oja, 1997).
The structure of GAGs has been subject to detailed
investigations. Biochemical techniques including sequen-
cing have been used to study GAG structure (Lindahl et al,
1998; Turnbull et al, 1999; Venkataraman et al, 1999).
Oligosaccharide sequencing techniques, however, are
complicated and only small oligosaccharides can be
characterized. Therefore, other approaches have been
probed, including immunological methods. Antibodies were
selected that react with HS (David et al, 1992; van den Born
et al, 1995), CS (Couchman et al, 1984; Caterson et al,
1990a; Sorrell et al, 1990), and KS (Caterson et al, 1983).
Using antibodies and biochemical techniques, the presence
of GAGs in human skin was determined (Sorrell et al, 1990).
HS is mainly located in basement membranes (Andriessen
et al, 1997), while CS is abundantly present in the papillary
dermis, and less in the reticular dermis. The major
chondroitin sulfate proteoglycan in skin is versican (Bern-
stein et al, 1995; Sorrell et al, 1999), which is associated
with elastic fibers (Bernstein et al, 1995), and plays a role in
Abbreviations: CS, chondroitin sulfate; C-4S, chondroitin-4 sulfate;
C-6S, chondroitin-6 sulfate; CSA, chondroitin sulfate A; CSC,
chondroitin sulfate C; CSE, chondroitin sulfate E; DE, dermis; DS,
dermatan sulfate; EP, epidermis; GAG, glycosaminoglycan; HS,
heparan sulfate; scFv, single-chain variable fragment
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cellular proliferation and tissue remodeling (Zimmermann
et al, 1994).
The anti-GAG antibodies currently used are of IgM
nature, which makes them difficult to handle. The phage
display technique forms an alternative to the traditional way
of antibody generation. Selection of antibodies by this in
vitro method is fast. Furthermore, antibodies against self-
antigens and poorly immunogenic targets, like CS, can be
more easily selected. Because the sequences of the
antibody genes are known, identification, optimization,
and labeling of antibodies is easy. The cloned antibodies
can be expressed as intrabodies to study GAG functions
(Jenniskens et al, 2003). Antibody genes of a large number
of species can be used including human, the latter being
attractive for future therapeutic use. Using the phage
display technique, a number of anti-HS/heparin antibodies
have been selected (van Kuppevelt et al, 1998; Jenniskens
et al, 2000; Dennissen et al, 2002; van de Westerlo et al,
2002). These antibodies react with different epitopes on the
HS chains. In this study, we have used the phage display
technique to specifically select human antibodies against
CS. We have used these antibodies to study the in situ
location of CS epitopes in normal skin and two skin
disorders, melanoma and psoriasis.
Results
Selection and characterization of anti-CS antibodies
Four rounds of panning using the phage display library
‘‘scFv library no. 1’’ (Nissim et al, 1994) were performed
using immobilized CSC (containing mainly C-6S) to select
antibodies reactive with CS. The phage titer increased
during selection from 105 individual clones in the first round
to 108 clones in the fourth round. Individual clones from the
third and fourth selection rounds were induced to produce
soluble antibodies, which were tested in ELISA for their
binding towards immobilized CS. Of the five CS-positive
clones from the third selection, three unique clones could
be identified. All 11 CS-positive clones from the fourth
selection were identical, but different compared to the
clones from the third selection. Clone data are displayed in
Table I. Antibodies IO3D9 and IO3H10 both belong to the
VH-1 family and have the same VH germline segment (DP-7).
Antibodies IO3H12 and IO4C2 both belong to the VH-3
family, but have a different VH germline segment, DP-46 and
DP-54, respectively. These clones are unique and were not
found in previous antibody selections to heparin and HS
(Jenniskens et al, 2000; Dennissen et al, 2002; van de
Westerlo et al, 2002). The antibody genes were subcloned
into vector pUC 119 HIS VSV containing the VSV-tag. The
use of the VSV-tag for immunofluorescence assays resulted
in reduced background compared to the original c-myc-tag.
The antibodies were tested for their reactivity with
different GAGs and polyanions immobilized onto an ELISA
plate (Fig 1). All antibodies reacted with CSC and also with
CSA. This is not surprising since both preparations contain
C-6S and C-4S, although CSC is enriched for C-6S and
CSA for C-4S. Since three of four antibodies showed a
higher reactivity with CSC, it is likely that they have a
preference for C-6S. The antibodies also reacted with highly
sulfated chondroitin sulfate E (CSE). Antibody IO3D9
showed a high reactivity with CSE compared to CSA or
CSC. Antibodies IO3H10, IO3H12, and IO4C2 bound to
immobilized CSE to about the same extent as to CSC. This
indicates that the IO3D9 epitope is different from the other
CS epitopes. All antibodies reacted exclusively with CS
except IO4C2, which also reacted with heparin in an ELISA
assay (Fig 1). No reactivity was observed with any of the
other investigated GAGs or polyanions. To further evaluate if
the antibodies recognized different CS epitopes, immuno-
histochemistry was performed using rat kidney sections,
which are a rich source of various GAG epitopes, with a
specific location (Dennissen et al, 2002). Marked differences
in staining pattern for all four antibodies were observed (Fig
2). All anti-CS antibodies reacted with the interstitial space
and peritubular capillaries. No staining of the glomerulus
was observed with antibodies IO3H10 and IO4C2 (Fig 2A,
D), whereas IO3H12 reacted weakly (Fig 2C) and IO3D9
strongly (Fig 2B). Only antibody IO3H12 stained the brush
border area of the tubules (Fig 2C). These data show that
the staining pattern in kidney is unique for all four anti-CS
antibodies, indicating that different CS epitopes are
recognized by these antibodies.
Sensitive detection of CS by anti-CS antibodies in
solution We also tested the reactivity of the anti-CS
antibodies with CSC and HS from bovine kidney in solution
(Fig 3). As a control we used IgM antibody CS-56, reactive
with CS (Avnur and Geiger, 1984). Binding of all antibodies
to immobilized CSC could be inhibited by CSC, but not
by HS, indicating that, also in solution, the antibodies











IO3D9 GIKHRHTQ 1 DP-7 3
IO3H10 AKRLDW 1 DP-7 1
IO3H12 MKTRLDV 3 DP-46 1
IO4C2 GKQRYS 3 DP-54 11
For each unique clone the CDR3-region amino acid sequence, the VH family, and the VH segment (DP nomenclature) (Tomlinson et al, 1992) are
indicated. The CDR3 sequences are shown in single-letter amino acid abbreviations. The Q in italic represents the translation of an amber codon to
glutamine in E. coli TG-1 supE strain.
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Figure 1
Reactivity of anti-CS antibodies with immobilized glycosaminogly-
cans. ELISA assay to determine the reactivity of the antibodies IO3H10
(A), IO3H12 (B), IO3D9 (C), and IO4C2 (D) towards immobilized
glycosaminoglycans and other polyanions. The results are presented
relative to the reactivity to CSC reactivity. CSA, chondroitin sulfate A
(mainly C-4S); CSC, chondroitin sulfate C (mainly C-6S); CSE,
chondroitin sulfate E, DEX, dextran sulfate; DNA, calf thymus DNA;
DS, dermatan sulfate; HEP, heparin; HSBK, heparan sulfate from bovine
kidney; HSIM, heparan sulfate from intestinal mucosa, HYA, hyaluronic
acid. Note the high reactivity for CSE of antibody IO3D9. Values are
given as mean  SD (n¼3).
Figure2
Evaluation of anti-CS antibodies using rat kidney immunoreactiv-
ity. Cryosections of rat kidney were incubated with antibodies and
detected by a Cy3-labeled anti-VSV-tag antibody. Note the difference
in staining pattern indicating the different CS epitopes detected by the
different antibodies. Arrows mark the glomerulus, and asterisks mark
the brush border. (A) IO3H10, (B) IO3D9, (C) IO3H12, (D) IO4C2. Scale
bar: 100 mm.
Figure3
Reactivity of anti-CS scFv antibody IO3H10 and anti-CS IgM CS-56
with CSC and HS in solution. Anti-CS antibodies IO3H10 and CS-56
were added to CSC and HS preparations, and transferred to CSC-
coated wells. Antibody binding of IO3H10 was detected using anti-VSV
mouse monoclonal antibody P5D4, followed by alkaline phosphatase-
conjugated rabbit anti-mouse IgG. Anti-CS-56 was detected using an
alkaline phosphatase-conjugated rabbit anti-mouse IgM. Enzymatic
activity was measured using p-nitrophenyl phosphate as a substrate.
Values represent the reactivity, relative to antibody binding without the
addition of a test substance, which was set to 100%. (’) CSC
(IO3H10), (&) HS (IO3H10), (  ) CSC (CS-56). Values are given as
mean  SD (n¼3).
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specifically bind CS. The IC50 dose, the amount of CS
resulting in 50% inhibition of binding, was about 1 mg per
mL for all anti-CS antibodies and 50 mg per mL for CS-56,
indicating that the phage display-derived anti-CS antibo-
dies allow a sensitive and specific detection of CS in
solution.
Next we determined the binding capacity of the
antibodies with different CS preparations in solution in
competition ELISA. The results for antibody IO3H10 are
shown in Fig 4. For all anti-CS antibodies, similar results
were obtained. Binding of immobilized CSC could be
inhibited with low concentrations of CSE, moderate con-
centrations of CSA, and relatively high concentrations of
CSC. No inhibition with HS was observed (Figs 3 and 4).
The IC50 dose of CSE is smaller than 0.1 mg per mL, for CSC
about 1 mg per mL, and for CSA about 10 mg per mL. This
indicates that the preference for antibody binding to the
different CS preparations in solution is in the following order:
CSE4CSC4CSA.
CS epitopes in normal skin and psoriasis Using the CS-
reactive antibodies, we investigated the expression and
location of CS epitopes in normal skin. Immunoreactivity of
the anti-CS antibodies with the papillary dermis, blood
vessels, and fibers in the dermis was observed (Fig 5A, B).
Anti-CS antibody staining in the papillary dermis overlaps
with collagen type IV staining (Fig 5C, D), indicating that CS
is located in the basement membrane. Anti-CS antibody
staining also co-localizes with elastin fibers in the dermis, as
indicated by autofluorescence of elastin (Fig 5E, F).
All scFv anti-CS antibodies and antibody CS-56 showed
similar results on different biopsies (n¼ 7) (Fig 6A, C, E, G).
Antibody IO3H12, but not the other antibodies, also stained
basal keratinocytes (Fig 6C, big arrow). In biopsies of
psoriatic skin (Fig 6B, D, F, H), the prominent CS location in
the papillary dermis was lost and a more diffuse staining
extending into the reticular dermis was observed (Fig 6B, D,
F, H). This was noticed in all cases investigated (n¼ 7). Also
the keratinocyte staining by antibody IO3H12 was lost in
psoriatic lesions (Fig 6D). The IgM antibody CS-56 showed
identical CS location in normal and psoriatic skin as the
phage-display-derived antibodies, and does not show
keratinocyte staining (Fig 6G). An irrelevant control single-
chain antibody TSCO1 (van de Westerlo et al, 2002) did not
stain the dermis and papillary dermis in normal and psoriatic
skin (Fig 6I, J), indicating that the reactivity of the antibodies
is specific. These data indicate that in psoriatic skin,
marked differences in CS epitope location occur compared
to normal skin.
CS epitopes in melanoma We also tested the presence of
CS epitopes in different stages of melanocytic tumor
development using the antibodies. All single-chain anti-
bodies showed a marked reactivity with melanoma metas-
tases, indicating a high abundance of the CS epitopes
(Fig 7A, C). Antibody CS-56 showed similar results (Fig 7E).
Figure 4
Reactivity of anti-CS antibodies with different CS preparations in
solution. Anti-CS antibody IO3H10 was added to CSA, CSC, CSE, or
HS preparations, and then transferred to CSC-coated wells. Antibody
binding of IO3H10 was detected using anti-VSV mouse monoclonal
antibody P5D4, followed by alkaline phosphatase-conjugated rabbit
anti-mouse IgG. Enzymatic activity was measured using p-nitrophenyl
phosphate as a substrate. Values represent the reactivity in percent
relative to antibodies without the addition of a test substance. (E) CSA,
(’) CSC,: CSE, (&) HS. Values are given as mean  SD (n¼ 3).
Figure5
Location of CS epitopes in normal skin. Cryosections of normal skin
were incubated with anti-CS antibodies IO3H10 (A, C, E) and IO3H12
(B, D, F) together with a collagen type IV antibody on the same section.
Elastin was detected by its autofluorescence (E, F). Bound antibodies
were visualized using fluorescently labeled secondary antibodies. CS
epitopes are detected in the papillary dermis and co-localize with
collagen type IV staining (see the asterisk) that is present in the
basement membrane. Staining of antibodies IO3H10 and IO3H12 also
correlates with the staining of elastic fibers (E, F) (marked by arrows).
Scale bar: 100 mm.
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To show the location of the ECM and the papillary dermis,
an Azan staining was performed (Fig 7I, J). The antibodies
reacted predominantly with ECM surrounding nests of
melanoma cells. In atypical nevi, the papillary dermis
was stained (Fig 7B, D, F). The papillary dermis showed a
much brighter staining than the reticular dermis, as was
observed in normal skin biopsies. We used single-
chain antibody TSCO1 as a specificity control. This anti-
body did not stain melanoma or atypical nevus sections
(Fig 7G, H).
To confirm GAG specificity of the anti-CS antibodies, we
performed digestions with chondroitinase ABC on tissue
sections (Fig 8). The reactivity of antibodies IO3H10,
IO3H12, and IO3D9 was abolished by digestion of kidney,
melanoma, atypical nevus psoriatic skin, and normal skin
with chondroitinase ABC, indicating that the antibodies
specifically detect GAGs. Staining of antibody IO4C2 is
reduced but not abolished by digestion with chondroitinase
ABC.
Figure 6
Detection of CS epitopes in normal and psoriatic skin. Cryosections
of normal (A, C, E, G, I ) and psoriatic skin (B, D, F, H, J ) were incubated
with anti-CS antibodies IO3H10 (a, b), IO3H12 (c, d), IO3D9 (e, f), CS-56
(G, H) and control single-chain antibody TSCO1 (I, J). Bound antibodies
were visualized using fluorescently labeled secondary antibodies. Note
that in the dermis (DE) of normal skin, CS epitopes are detected in the
papillary dermis, while in psoriatic skin they are equally distributed in
the reticular dermis, as well as the papillary dermis. Basal keratinocytes
are stained by antibody IO3H12 (C, marked by a big arrow) in the
epidermis (EP). The area of interest is marked by an arrow and enlarged
in the lower corner. Basal keratinocyte staining is not detected in
psoriatic skin (D). In contrast to IO3H12, antibodies IO3H10, IO3D9,
and CS-56 do not stain basal keratinocytes in normal and psoriatic
skin. Control single-chain antibody TSCO1 does not stain the papillary
dermis. Scale bar: 100 mm.
Figure7
Detection of CS epitopes in different stages of melanocytic tumor
development. Reactivity of anti-CS antibodies IO3H10 (A, B), IO3H12
(C, D) CS-56 (E, F), and control antibody TSC01 (G, H) with a human
melanoma metastasis (A, C, E, G) and atypical nevus (B, D, F, H).
Cryosections were incubated with anti-CS antibodies. Bound anti-
bodies were visualized using fluorescently labeled secondary anti-
bodies. An Azan staining marks the ECM in melanoma (I ) and the
location of the dermis in dysplastic nevus (J). Arrows mark the ECM in
melanoma metastases. Intense staining of ECM in melanoma metas-
tases was observed (A, C, E). In the dermis (DE) of atypical nevi, the
staining of the papillary dermis was more intense than in the reticular
dermis (B, D, F). The epidermis (EP) is not stained. Scale bar: 100 mm.
ANTI-CHONDROITIN SULFATE SINGLE-CHAIN ANTIBODIES 711122 : 3 MARCH 2004
Discussion
CS is a class of GAGs, which are linear polysaccharides
located in the extracellular matrix and on cells. The CS
backbone is made up of alternating b1,3 and b1,4
glycosidic-linked glucuronic acid (GlcUA) and N-acetyl
galactosamine (GalNAc) residues. CS can carry either a
4-sulfate and/or a 6-sulfate on the GalNAc moiety, and a
2-sulfate on the GlcUA moiety (Calabro et al, 2000). A 3-O-
sulfate on GlcUA has also been demonstrated. Given this
structural variability, there are theoretically over a million
possibilities for a decasaccharide. This makes CS, with an
average length of 50–100 disaccharides, a hypervariable
molecule. The selective binding of proteins to CS is dictated
by the sulfation pattern. Interferon gamma (Fernandez-
Botran et al, 1999; Hurt-Camejo et al, 1999), low-density
lipoprotein (Kaplan and Aviram, 2000), tumor necrosis
factor-stimulated gene-6 (TSG-6) (Park et al, 2000), growth
factors like midkine (Zou et al, 2000), and ECM molecules
like tenascin X (Elefteriou et al, 2001) are some examples of
proteins that bind to CS. Highly sulfated CS (CSE), which is
4- and 6-sulfated, has the capacity to bind additional
heparin-binding proteins like FGFs (Deepa et al, 2002). In
contrast to CS–protein interactions, the binding of heparin
and HS with proteins has been subject to a large number of
studies (Bernfield et al, 1999; Capila and Linhardt, 2002). As
a result, much is known about the structural diversity in HS
and heparin responsible for protein binding. To analyze
structural diversity of CS in skin and of CS alterations in skin
pathology, we have selected antibodies to CSC, which
mainly contains C-6S. Four antibodies—IO3H10, IO3D9,
IO3H12, and IO4C2—were selected. The reactivity and VH
sequence of these anti-CS antibodies are quite different
from previously selected anti-HS antibodies.
In this study we have investigated the binding of the
antibodies to CSA (mainly 4-sulfated), CSC (mainly 6-
sulfated), and CSE (both 4- and 6-sulfated). All four
antibodies show a specific reactivity with CSA, CSC, and
CSE. Surprisingly, only antibody IO3D9 shows a much
higher binding capacity to immobilized CSE compared to
the other antibodies. This shows that the nature of the
IO3D9 epitope is quite different from the epitopes recog-
nized by the other three antibodies. In solution, all
antibodies have a preference for CSE above CSC (Fig 4).
CSA is bound more weakly than CSC. The difference of
reactivity to CSE in solution compared to immobilized CSE
is probably related to differences in immobilization of the
GAG preparations. All anti-CS antibodies recognize unique
epitopes in native CS chains. Different distribution patterns
in rat kidney and human skin, and a distinct immuno-
reactivity towards CS preparations illustrate that the anti-CS
antibodies recognize structurally different CS epitopes.
The first anti-CS antibodies that were described in the
literature detected chondroitinase-treated CS and react
with an unsaturated uronic acid residue, which was formed
after digestion (Couchman et al, 1984; Caterson et al, 1985).
Antibodies recognizing unmodified CS have also been
identified (Yamagata et al, 1987; Sorrell et al, 1990;
Hemming et al, 1994), including polyclonal antibodies
(Karamanos et al, 1995). These antibodies however have
either not been characterized completely (Hemming et al,
1994) or CS specificity is not always proven. The most
widely used and best characterized antibody is CS-56,
reactive with C-4S and C-6S (Avnur and Geiger, 1984). Most
antibodies that detect unmodified CS chains are mouse
antibodies of the IgM subclass. This limits their possibilities.
Because of the few specific antibodies that have been
described, alternative antibodies detecting unmodified CS
chains are clearly of use to study the structure of CS. The
human scFv anti-CS antibodies described here can be used
as tools to visualize structural diversity in CS, as was
previously illustrated with other antibodies in various tissues
and model systems (Avnur and Geiger, 1984; Caterson et al,
Figure 8
Determination of anti-CS antibody specificity by chondroitinase
treatment. Reactivity of anti-CS antibody IO3H12 was determined
after treatment with chondroitinase ABC (B, D, F, H, J) or with
chondroitinase buffer alone (A, C, E, G, I) on rat kidney (a, b), human
melanoma (C, D), human atypical nevus (E, F), human psoriatic skin (G,
H), and human normal skin (I, J). Cryosections were incubated with or
without chondroitinase ABC and subsequently with anti-CS antibody
IO3H12. Bound antibodies were visualized using fluorescently labeled
secondary antibodies. Note that the staining of antibody IO3H12 is
completely lost in all tissue sections after treatment with chondroitinase
ABC. Scale bar: 100 mm.
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1985; Caterson et al, 1990b; Sorrell et al, 1990, 1993, 1999).
Since the cDNA of the single-chain antibodies is available,
antibodies can be produced and purified in large quantities.
In addition, cells can be transfected with antibody cDNA
and induced to produce antibodies. This opens new
avenues to study cell biology of CS epitopes in vitro and
in vivo, as was recently demonstrated for anti-HS antibodies
(Jenniskens et al, 2003). In this study we have investigated
CS immunoreactivity in normal skin and two skin diseases,
psoriasis and melanoma.
In normal skin the investigated CS epitopes are mainly
expressed in the papillary dermis, although antibody
IO3H12 also stains the basal keratinocytes. The CS
epitopes are located in the basement membrane, blood
vessels, and around elastin fibers (Fig 5). The dermal
expression of these antibodies is comparable to the
expression of the traditional antibody CS-56 (Fig 6) and
also to antibody 6C3 (Sorrell et al, 1990). Chondroitinase
treatment followed by antibody detection indicates that
C-4S expression is located in the epidermis and the entire
dermis, with higher expression in the papillary dermis, while
C-6S expression is restricted to the papillary dermis (Sorrell
et al, 1990). An antibody that detects CS in basal
keratinocytes (PG-4) like IO3H12 has also been described
(Sorrell et al, 1999). Other anti-CS antibodies detect CS in
the epidermis or reticular dermis (Sorrell et al, 1990). The
expression of the proteoglycan versican is detected in the
subepidermal region and associated with elastic fibers
(Zimmermann et al, 1994; Sorrell et al, 1999), and is age
dependent (Willen et al, 1991). Like IO3H12 also the basal
keratinocytes are stained. The single-chain anti-CS anti-
bodies show an expression that is focussed in the papillary
dermis. Decorin also shows a higher expression in the
papillary dermis (Schonherr et al, 1993); this proteoglycan
however is expressed throughout the dermis. Therefore, the
expression of the CS epitopes partially correlates with the
expression proteoglycan core proteins.
We have detected alterations in the distribution of CS in
psoriasis. All CS antibodies showed a loss of the focussed
expression in the papillary dermis observed in normal skin.
Instead, the entire dermis shows a diffuse staining in all
psoriatic lesions investigated. No alterations of CS or CS
proteoglycans have been described previously, but altera-
tions of hyaluronan (Wells et al, 1991) and HS (Seyger et al,
1997) have been reported. For hyaluronan, a diffuse
meshwork, comparable to the immunoreactivity pattern
observed for the anti-CS antibodies, was observed in six of
16 psoriatic patients (Wells et al, 1991). A loss of
immunoreactivity of two anti-HS antibodies, JM-13 and
JM-403, was observed in psoriatic skin (Seyger et al, 1997).
This clearly indicates that in psoriatic lesions alterations in
GAGs occur. It has been suggested that disturbed
glycosaminoglycan location and expression in psoriatic
lesions leads to malfunction of the basement membrane
and protein leakage, thereby contributing to the disease
process (Verschoore et al, 1990).
In melanoma metastasis the CS epitope expression
detected by our anti-CS antibodies is high without excep-
tion (Fig 7), especially in ECM structures. In atypical nevi,
the expression is restricted to the papillary dermis and
blood vessels in the dermis and is not significantly different
from that in normal skin. The presence of high amounts of
CS in melanoma metastases was observed before in a
previous study (Smetsers et al, 2003) and is in line with CS
expression in other types of cancer (Yamori et al, 1988;
Adany et al, 1990; Ricciardelli et al, 1997; Ricciardelli et al,
1999; Martins et al, 2000; Theocharis et al, 2000). The
expression pattern does not resemble that of CD44 or
HMW-MAA, which are expressed on the surface of nevus
and melanoma cells (Manten-Horst et al, 1995; Smetsers
et al, 2003). The expression of versican and melanoma-
associated proteoglycan (mel-CSPG), however, is low in
atypical nevi and high in melanoma, and also their
expression is cell-associated (Touab et al, 2002, 2003).
A high amount of CS in tumors could allow tumors to
store many specific CS-binding proteins, promoting tumor
growth. Tumors treated with chondroitinase show reduced
growth and metastasis formation, further indicating the
involvement of CS (Denholm et al, 2001). The expression of
melanoma chondroitin sulfate proteoglycan that is used as
a marker in melanoma also indicates the role of CS in
melanoma (Pluschke et al, 1996; Geiser et al, 1999). Finally,
CS targeting liposomes can be used to therapeutically
target drugs to metastases (Lee et al, 2002). The anti-CS
antibodies selected, recognize CS that is located in ECM
structures in between the tumor cells. These structures
have a prognostic significance in uveal melanoma (Folberg
et al, 1992) and may provide an additional way of fluid
transport in cutaneous melanoma (Bittner et al, 2000). These
data indicate the importance of CS in the extracellular
matrix of melanoma and indicate that CS might be an
important factor contributing to the malignant process.
Both melanoma and psoriasis show increased angiogen-
esis. For treatment, angiogenesis inhibitors are now tested
in clinical trials (Kumar and Li, 2001). The angiogenesis
inhibitor AE-941 shows promising effects for the treatment
of psoriasis (Dupont et al, 1998; Sauder et al, 2002). This
angiogenesis inhibitor contains shark cartilage extract,
which contains large amounts of C-6S. In fact, the anti-CS
antibodies in this study were selected against C-6S from
shark cartilage. It is possible that treatment of psoriatic
lesions with CS might complement for the local loss of
certain CS epitopes or immobilize proteins, normally bound
to CS in normal skin. The human scFv anti-CS antibodies
described in this study may be useful in the purification and
analysis of those CS saccharide epitopes that are involved
in the pathogenesis of melanoma and psoriasis. This may
lead to the synthesis of glycomimetics to be used for
treatment. Also, since the antibodies are of human nature,
immunotherapy may be an option.
We conclude that the four novel anti-CS antibodies
described here are useful tools to study skin biology
because they detect different CS epitopes and identify
alterations of CS in melanoma and psoriasis.
Materials and Methods
The study was performed according to the ethical guidelines following
the Declaration of Helsinki. It was approved by the University Medical
Center Nijmegen and performed under Ministry of Health license GGO
01-075.
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Antibody selection by phage display In this study the semi-
synthetic single-chain variable fragment (scFv) library no. 1 (Nissim
library) was used (Nissim et al, 1994). The library was stored as a
glycerol stock in Escherichia coli (E. coli) TG1 bacteria (K12, D(lac-
pro), supE, thi, hsdD5/F0traD36, proAþBþ , lacIq, lacZDM15). This
glycerol stock (50 mL) was inoculated in 50 mL of 2xTY medium
containing 1% wt/vol casein, 1.6% wt/vol bacto tryptone (Gibco
BRL, Life Technologies, Paisley, Scotland), 0.5% wt/vol NaCl.
Bacteria were grown under constant rotation at 371C until an A600
of 0.5 was reached. Then 50 mL 1012 plaque-forming units per mL
helper phage VCS-M13 (Stratagene, La Jolla, California) was
added to 10 mL of this culture and the phagemid-containing
bacteria were infected with the helper phage by incubating for
30 min at 371C without shaking. Cells were collected by
centrifugation (10 min, 2500  g, 221C) and resuspended in 300
mL preheated (301C) 2xTY medium with 100 mg per ml ampicillin
(Sigma, St Louis, Missouri) and 25 mg per ml kanamycin (Life
Technologies, Paisley, Scotland). Bacteria were cultured for 16 h at
301C with shaking. Polystyrene 3 mL tubes (Greiner GmbH,
Frickenhausen, Germany) were coated for 16 h with chondroitin
sulfate C (CSC, 10 mg per mL) (Sigma). CSC mainly contains
chondroitin 6-sulfate (C-6S), and also chondroitin 4-sulfate (C-4S).
The tubes were washed with phosphate-buffered saline containing
0.1% Tween-20 (PBST). Non-specific binding sites were blocked
by the addition of 2% non-fat dried milk (Marvel, Chivers Ireland,
Dublin, Ireland) in PBST for 60 min under rotation, followed by
washing five times with PBST. Bacteria were collected by
centrifugation (10 min, 2500  g, 41C) and phages were precipi-
tated by the addition of 10 mL PEG/NaCl to 40 mL of the
supernatant for 30 min on ice. The phages were collected by
centrifugation (30 min, 5000  g, 41C), supernatant was removed,
and the pellet resuspended in 1 mL milliQ water. One microliter of
phage suspension was kept for phage titration. The rest of the
precipitated phages were transferred into the CS-coated tube.
Phages were allowed to bind to the tube for 30 min under rotation,
and then 90 min without rotation. The tube was washed 20 times
with PBST, and subsequently 20 times with PBS. Bound phages
were eluted by incubation in 1 mL 100 mM triethylamine for 10 min
under rotation. The eluate was neutralized by the addition of 0.5
mL 1 M Tris/HCl (pH 7.3). This suspension, containing the selected
phages, was used to infect 9 mL of TG1 bacteria (A600¼ 0.5).
Phage-containing samples before and after selection were also
used to infect TG1 to establish the phage titer. Infection was
performed 30 min at 371C without rotation and 90 min with
rotation. A sample of 100 mL of the infected bacteria was plated
onto TYE-agar plates (TY with bacto agar containing 1% (wt/vol)
glucose and 100 mg per ml ampicillin). To the culture infected with
phages from CS-binding selection, ampicillin (100 mg per mL) was
added and this culture was incubated with shaking for 60 min at
371C. The culture was superinfected with 50 mL VSC-M13 helper
phages for 30 min at 371C without rotation. After superinfection
and centrifugation (10 min, 2500  g, 221C), the bacterial pellet
was resuspended in 50 ml 2  TY medium with 100 mg per ml
ampicillin, which was preheated at 301C. The culture was
incubated with shaking for 60 min at 371C, and then 25 mg per
mL kanamycin was added to select for bacteria containing the
helper phage. This culture was incubated shaking for 16 h at 301C
to produce phages. Four consecutive rounds of selection were
performed. After each selection round, the phage titer was
determined. Phage suspensions taken before and after the
selection were tested.
Induction of antibody production by individual clones Bacter-
ial colonies were transferred to a flat-bottom 96-well plate (Greiner,
Frickenhausen, Germany) containing 100 mL per well 2  TY
medium containing 100 mg per mL ampicillin and 1% (wt/vol)
glucose. These plates were incubated for 16 h with shaking at
371C. Two microliters of the bacterial suspensions were transferred
to corresponding wells in a round-bottom 96-well plate (Greiner)
containing 2  TY (150 mL per well) with ampicillin (100 mg per mL)
and 0.1% (wt/vol) glucose. These plates were incubated at 371C
with shaking until A600 reached about 0.5. The original plates were
stored at 801C containing 20% glycerol. To the round-bottom
plates, IPTG was added to a final concentration of 1 mM and these
plates were incubated for 16 h at 301C under constant rotation.
Determination of antibody reactivity by ELISA A 96-well flat-
bottom plate was incubated for 16 h with 100 mL of a 10 mg per mL
test substance solution in coating buffer. The test substances were
HS from bovine kidney (Seikagaku Kogyo, Tokyo, Japan) and HS
from intestinal mucosa, heparin from porcine intestinal mucosa, DS
from pig skin, chondroitin sulfate A (CSA) (mainly C-4S) from
bovine trachea and chondroitin sulfate C (CSC) (mainly C-6S) from
shark cartilage, dextran sulfate, calf’s thymus DNA and hyaluronic
acid from rooster comb (all from Sigma), and chondroitin sulfate E
(CSE) (Seikagaku Kogyo). After washing, 50 mL of the supernatant
of the IPTG-induced bacteria was mixed with 50 mL 2% (wt/vol)
BSA in PBST in each well. Alternatively, a 10-fold diluted antibody
preparation from the periplasm (prepared as described (van de
Westerlo et al, 2002)) in 1% (wt/vol) BSA in PBS was used.
Antibody TSCO1 (van de Westerlo et al, 2002) served as a negative
control while antibody EW4G1 (van de Westerlo et al, 2002) served
as a positive control in these experiments. To test antibody-binding
properties in solution, which are independent of coating properties,
we performed competition ELISA. For competition ELISA, antibody
dilutions were incubated in C-6S-coated wells together with
different concentrations of test substance as a competitor for
90 min at 221C. The plates were washed three times with PBST.
Since these antibodies contain a c-myc tag, we used this tag for
the detection of antibody binding. A hybridoma supernatant of the
anti-c-myc tag mouse monoclonal antibody 9E10 (Boehringer
Mannheim, Mannheim, Germany), diluted 2-fold in 2% (wt/vol) BSA
in PBST, was added to the wells (100 mL per well). Also antibodies
with a VSV-tag were used (see the section on subcloning). For the
detection of bound VSV-tagged antibody, a hybridoma supernatant
of anti-VSV-tag mouse monoclonal antibody P5D4, diluted 2-fold in
2% (wt/vol) BSA in PBST, was added (100 mL per well). The plates
were incubated for 90 min at 221C and washed three times with
PBST. Then 1000-fold-diluted alkaline phosphatase-conjugated
rabbit anti-mouse IgG (Dakopatts, Glostrup, Denmark) in 1% (wt/
vol) BSA in PBST was added (100 mL per well) and the plates were
incubated for 60 min at 221C. The plates were washed three times
with PBSTand three times with PBS. Enzyme activity was detected
the addition of 100 mL per well of 1 mg per mL 4-nitrophenylpho-
sphate disodium salt in a solution of 1 mM diethanolamine, 0.5 mM
MgCl2, pH 9.8. Absorbance was measured using an ELISA reader
at a wavelength of 405 nm.
Sequence analysis of the antibody region of the selected
clones Phagemid DNA was purified from the bacterial pellet from
an overnight culture of the selected clones by using the QIA prep
spin mini kit (Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s instructions. The DNA was stored at 201C.
Sequencing of the antibody genes was performed on an ABI
Prism 3700 DNA analyser (Applied Biosystems, Foster City,
California) using primers PelBseq (50-CCGCTGGATTGTTAT-
TACTC-30) or For Link Seq RIC (50-GCCACCTCCGCCTGAACC-
30) and the BigDye terminator kit (Applied Biosystems) according to
the manufacturer’s instructions. VH families and VH segment
(DP nomenclature) (Tomlinson et al, 1992) were determined by
comparison with known VH sequences using DNAPLOT software
on http://www.mrc-cpe.cam.ac.uk/.
Subcloning of the antibody sequence into pUC119 HIS VSV
vector The antibody coding sequence was digested from the
vector using restriction enzymes NotI and NcoI (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions, and
ligated into a similarly digested vector pUC119 (His)8 VSV
containing a His(8)-tag and a VSV-tag. The sequence was verified
as described above.
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Preparation of antibody-containing periplasmic fractions An
overnight culture of the different bacterial clones was diluted 100-
fold in 500 mL sterile 2  TY medium containing ampicillin (100 mg
per mL) and 0.1% (wt/vol) glucose and incubated shaking at 371C
until the A600 reached 0.6. Then IPTG was added to a final
concentration of 1 mM to induce antibody production. The cultures
were incubated for 3 h at 301C, cooled on ice for 15 min, and then
centrifuged for 10 min at 2500  g at 41C. Cells were resuspended
in 5 mL of a solution containing 200 mM sodium borate, 160 mM
NaCl and EDTA-free protease inhibitors (Boehringer Mannheim,
Mannheim, Germany), and centrifuged for 20 min at 5000  g at
41C. After filtration through a 0.45 mm filter, the fractions were
dialyzed for 16 h against PBS at 41C and stored in small aliquots at
201C.
Immunohistochemistry Seven normal skin biopsies, seven psor-
iatic skin biopsies, five human melanoma metastases, and three
atypical nevi were frozen in liquid nitrogen and stored at 801C.
Organs of adult Wistar rats were frozen. Cryosections of 5 mm were
made, dried, and stored at 801C until use. Before use, the
cryosections were thawed, air dried for 1 h, and rehydrated with
PBS. Occasionally, cryosections were subjected to enzyme
digestion with chondroitinase ABC (Sigma), 1 IU per mL in
25 mM Tris/HCl, pH 8.0, to digest dermatan sulfate and
C-6S and C-4S. Alternatively chondroitinase C (Sigma) was used
to digest C-6S only.
Sections were incubated with the antibodies in PBS containing
1% BSA. Periplasmic fractions were diluted 10-fold, anti-CS-
antibody CS-56 (Sigma) was used at a 50-fold dilution, and goat
anti-collagen type IV (Southern Biotechnology Associates, Bir-
mingham, Alabama) was used at a 20-fold dilution. Sections were
washed three times for 5 min with PBS and subsequently
incubated with secondary antibodies diluted in PBS containing
1% BSA. A 500-fold-diluted Cy3-conjugated anti-VSV-tag anti-
body P5D4 (Sigma) was used for the detection of VSV-tagged
single-chain antibodies, a 100-fold-diluted goat anti-mouse IgM
FITC (Sigma) was used for the detection of bound CS-56, and a
100-fold donkey anti-goat Alexa 488 (Molecular Probes Inc.,
Eugene, OR) was used for the detection of collagen type IV.
Sections were washed again three times and fixed with methanol.
Next the sections were embedded in Mowiol (Calbiochem, La
Jolla, California) and immunoreactivity was visualized using an
Axioscope fluorescence microscope equipped with a Nikon
DXM1200 digital camera (Nikon, Tokyo, Japan).
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